Evidence map›Paper›PMID 32592449›Full record

ArticleMolecular genetics & genomic medicine2020

TP53 p.Arg337His geographic distribution correlates with adrenocortical tumor occurrence.

Ana L Seidinger, Isabel P Caminha, Maria J Mastellaro, Carmen S Gabetta, Alexandre E Nowill, Vitória R P Pinheiro, José A Yunes

Open access · goldAbstract read
In one paragraph

Article in Molecular genetics & genomic medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Reconstructing the Origin and Demographic Expansion of the TP53 p.R337H Founder Variant in Brazil.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ana L SeidingerMolecular Biology Laboratory, Centro Infantil Boldrini, Campinas, São Paulo, Brazil.ORCID 0000-0002-9023-4649
Isabel P CaminhaIntegrated Center of Oncohematology Research in Childhood, State University of Campinas, Campinas, São Paulo, Brazil.
Maria J MastellaroPediatric Oncology, Centro Infantil Boldrini, Campinas, São Paulo, Brazil.
Carmen S GabettaIntegrated Center of Oncohematology Research in Childhood, State University of Campinas, Campinas, São Paulo, Brazil.
Alexandre E NowillIntegrated Center of Oncohematology Research in Childhood, State University of Campinas, Campinas, São Paulo, Brazil.
Vitória R P PinheiroIntegrated Center of Oncohematology Research in Childhood, State University of Campinas, Campinas, São Paulo, Brazil.
José A YunesMolecular Biology Laboratory, Centro Infantil Boldrini, Campinas, São Paulo, Brazil.ORCID 0000-0002-1316-3525
Universidade Estadual de Campinas (UNICAMP) · BRCentro Infantil Boldrini · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe p.Arg337His mutation of the TP53 is the most frequent germline missense variant associated with cancer described so far in this gene. It is mainly found in the South and Southeastern regions of Brazil, where it has been associated with a high incidence of pediatric adrenocortical (ACT) and choroid plexus tumors. The frequency and geographic distribution of this mutation is largely unknown, except for the Parana State, where a mean prevalence of 0.27% was reported. In the present study, we developed a high-throughput method for p.Arg337His genotyping, what allowed us to determine the frequency and geographic distribution of this mutation in a cohort from the most populous state in Brazil.

methodsConsecutive samples from 31,612 newborns from São Paulo State were screened for p.Arg337His. The allelic discrimination was done by real-time polymerase chain reaction (PCR) and the presence of haplotype A3 in carriers was examined by using allele-specific oligonucleotide PCR, followed by nested-PCR to detect the SNP rs9894946.

resultsWe found 67 (0.21%) samples positive for this mutation. The highest p.Arg337His frequencies were found in the cities close to the boundary between São Paulo and Minas Gerais State. No association could be found between p.Arg337His and gender, ethnicity, premature birth or twinning. Remarkably, a trend was found between the geographic distribution of p.Arg337His carriers and occurrence of ACT.

conclusionWe presented for the first time the p.Arg337His frequency among individuals unselected for any disease from a subset of the São Paulo State, the most populous in Brazil. The allele discrimination assay we presented here has proven to be a reliable and efficient method for high-throughput genotyping. ACT was found to be a good sentinel cancer to suppose p.Arg337His presence in our region.

Indexed as

Gene FrequencyMutation, MissenseAdrenal Cortex NeoplasmsBrazilFemaleGenotyping TechniquesHumansMalePopulationPrevalenceTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53genetic counselinghigh-throughput genotypingp.Arg337Hispediatric oncologyTP53

Identifiers

PMID32592449
PMCPMC7503091
OpenAlexW3037264682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.